Skip to main content

Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

Publication ,  Journal Article
Sullivan, KM; Goldmuntz, EA; Keyes-Elstein, L; McSweeney, PA; Pinckney, A; Welch, B; Mayes, MD; Nash, RA; Crofford, LJ; Eggleston, B; Khanna, D ...
Published in: N Engl J Med
January 4, 2018

BACKGROUND: Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma) often has a devastating outcome. We compared myeloablative CD34+ selected autologous hematopoietic stem-cell transplantation with immunosuppression by means of 12 monthly infusions of cyclophosphamide in patients with scleroderma. METHODS: We randomly assigned adults (18 to 69 years of age) with severe scleroderma to undergo myeloablative autologous stem-cell transplantation (36 participants) or to receive cyclophosphamide (39 participants). The primary end point was a global rank composite score comparing participants with each other on the basis of a hierarchy of disease features assessed at 54 months: death, event-free survival (survival without respiratory, renal, or cardiac failure), forced vital capacity, the score on the Disability Index of the Health Assessment Questionnaire, and the modified Rodnan skin score. RESULTS: In the intention-to-treat population, global rank composite scores at 54 months showed the superiority of transplantation (67% of 1404 pairwise comparisons favored transplantation and 33% favored cyclophosphamide, P=0.01). In the per-protocol population (participants who received a transplant or completed ≥9 doses of cyclophosphamide), the rate of event-free survival at 54 months was 79% in the transplantation group and 50% in the cyclophosphamide group (P=0.02). At 72 months, Kaplan-Meier estimates of event-free survival (74% vs. 47%) and overall survival (86% vs. 51%) also favored transplantation (P=0.03 and 0.02, respectively). A total of 9% of the participants in the transplantation group had initiated disease-modifying antirheumatic drugs (DMARDs) by 54 months, as compared with 44% of those in the cyclophosphamide group (P=0.001). Treatment-related mortality in the transplantation group was 3% at 54 months and 6% at 72 months, as compared with 0% in the cyclophosphamide group. CONCLUSIONS: Myeloablative autologous hematopoietic stem-cell transplantation achieved long-term benefits in patients with scleroderma, including improved event-free and overall survival, at a cost of increased expected toxicity. Rates of treatment-related death and post-transplantation use of DMARDs were lower than those in previous reports of nonmyeloablative transplantation. (Funded by the National Institute of Allergy and Infectious Diseases and the National Institutes of Health; ClinicalTrials.gov number, NCT00114530 .).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

January 4, 2018

Volume

378

Issue

1

Start / End Page

35 / 47

Location

United States

Related Subject Headings

  • Young Adult
  • Transplantation, Autologous
  • Transplantation Conditioning
  • Scleroderma, Systemic
  • Middle Aged
  • Male
  • Kaplan-Meier Estimate
  • Intention to Treat Analysis
  • Infections
  • Immunosuppressive Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sullivan, K. M., Goldmuntz, E. A., Keyes-Elstein, L., McSweeney, P. A., Pinckney, A., Welch, B., … SCOT Study Investigators, . (2018). Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med, 378(1), 35–47. https://doi.org/10.1056/nejmoa1703327
Sullivan, Keith M., Ellen A. Goldmuntz, Lynette Keyes-Elstein, Peter A. McSweeney, Ashley Pinckney, Beverly Welch, Maureen D. Mayes, et al. “Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.N Engl J Med 378, no. 1 (January 4, 2018): 35–47. https://doi.org/10.1056/nejmoa1703327.
Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, et al. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med. 2018 Jan 4;378(1):35–47.
Sullivan, Keith M., et al. “Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.N Engl J Med, vol. 378, no. 1, Jan. 2018, pp. 35–47. Pubmed, doi:10.1056/nejmoa1703327.
Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE, SCOT Study Investigators. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med. 2018 Jan 4;378(1):35–47.

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

January 4, 2018

Volume

378

Issue

1

Start / End Page

35 / 47

Location

United States

Related Subject Headings

  • Young Adult
  • Transplantation, Autologous
  • Transplantation Conditioning
  • Scleroderma, Systemic
  • Middle Aged
  • Male
  • Kaplan-Meier Estimate
  • Intention to Treat Analysis
  • Infections
  • Immunosuppressive Agents